Evidence map›Paper›PMID 29471300›Full record

Trial reportOncology2018

Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.

Soham D Puvvada, José M Guillén-Rodríguez, Jessica Yan, Lora Inclán, Kara Heard, Xavier I Rivera, Faiz Anwer, Daruka Mahadevan, Jonathan H Schatz, Daniel O Persky

Open access · bronzeAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Soham D PuvvadaDivision of Hematology-Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona, USA.
José M Guillén-RodríguezDivision of Hematology-Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona, USA.
Jessica YanInternal Medicine Residency Program, Department of Medicine, University of Arizona, Tucson, Arizona, USA.
Lora InclánUniversity of Arizona Cancer Center, Tucson, Arizona, USA.
Kara HeardUniversity of Arizona Cancer Center, Tucson, Arizona, USA.
Xavier I RiveraUniversity of Arizona Cancer Center, Tucson, Arizona, USA.
Faiz AnwerDivision of Hematology-Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona, USA.
Daruka MahadevanDivision of Hematology-Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona, USA.
Jonathan H SchatzDivision of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
Daniel O PerskyDivision of Hematology-Oncology, Department of Medicine, University of Arizona Cancer Center, Tucson, Arizona, USA.
University of Arizona · USUniversity of Miami · US

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Dan Theodorescu · 1985 to 2026
$110.2M
6 · The paper itself

Abstract

backgroundRadioimmunotherapy (RIT) is effective in treating relapsed/refractory follicular lymphoma (FL), with durable remissions in first-line consolidation. We hypothesized that RIT with ibritumomab tiuxetan (Zevalin®) would result in durable remissions by eliminating minimal residual disease after cytoreduction.

methodsPatients with FL received 2 cycles of ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) every 28 days, followed by Zevalin 4-6 weeks later if there was no disease progression and bone marrow biopsy showed < 25% involvement.

resultsTwenty-eight patients were treated, with a median age of 61 years, median of 3 prior therapies, 49% high-risk disease (Follicular Lymphoma International Prognostic Index, FLIPI), and 39% progressive disease. Three patients did not receive Zevalin due to residual bone marrow involvement. The main toxicities were cytopenias, with 11% febrile neutropenia. The overall response rate (ORR) was 72%, with 45% achieving complete response. With a median follow-up of 73 months, 1-year progression-free survival (PFS) was 38%, and median PFS was 10 months, but median overall survival (OS) was not reached.

conclusionThe study did not reach its primary endpoint of a 1-year PFS of 67.3%. Reasons for this could include low accrual, high-risk disease, and inadequate debulking provided by 2 cycles of ESHAP. However, this protocol was associated with tolerable toxicity, high ORR, and high OS. Further studies would optimize debulking and focus on high-risk FL patients.

Indexed as

RadioimmunotherapyAgedAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsCisplatinClinical Trials, Phase II as TopicCombined Modality TherapyCytarabineDisease-Free SurvivalEtoposideFemaleHumansLymphoma, FollicularLymphoma, Non-HodgkinMaleMethylprednisoloneAntibodies, MonoclonalCisplatinCytarabineEtoposideibritumomab tiuxetanMethylprednisoloneCD20Follicular lymphomaIndolent non-Hodgkin lymphomaPhase II trialRelapsed/refractory lymphoma

Identifiers

PMID29471300
PMCPMC6050637
OpenAlexW2790380171

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.